Chase Pharmaceuticals, an early stage, product based, specialty pharmaceutical company located in Washington DC, focuses on the identification and initial clinical development of better medications for the treatment of neurologic and psychiatric disease.

By leveraging management's ability to identify breaking technical opportunities for improving the treatment of central nervous system disorders as well as to successfully develop pharmaceutical products, CPC can rapidly advance novel neuropsychopharmacologic drugs from bench to bedside.

CPC is well positioned to succeed based on its proven drug candidate selection and clinical development capabilities combined with a business model that maximizes capital efficiency.

The company thus provides new hope for those now suffering from such intractable brain disorders as Alzheimer's and Parkinson's disease, depression, epilepsy and neuropathic pain.